Lower plasma levels of adiponectin are associated with prevalence and incidence of type 2 diabetes and cardiovascular disease (CVD), and higher levels of this molecule are associated with protection from cardiometabolic risk (2–4). Here, ADIPOQ is linked to type 2 diabetes mellitus.